Long COVID: which symptoms can be attributed to SARS-CoV-2 infection?

Brightling, Christopher; Evans, Rachael A.

doi:10.1016/s0140-6736(22)01385-x

Cited by 30 publications

(21 citation statements)

References 11 publications

(16 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several terms, such as long COVID or Post-COVID Conditions, Post-COVID-19 Syndrome, and PASC, have been proposed. And the heterogeneity has been observed in long COVID across studies [ 16 ]. The estimated prevalence depends on follow-up duration, population and symptoms for defining long COVID.…”

Section: Discussionmentioning

confidence: 99%

Healthy outcomes of patients with COVID-19 two years after the infection: a prospective cohort study

Liao

et al. 2022

Emerging Microbes & Infections

View full text Add to dashboard Cite

The long-term effect of coronavirus disease 2019 (COVID-19) has been rarely known. This study aimed to investigate healthy outcomes of COVID-19 survivors up to 2 years after the infection. A total of 155 COVID-19 patients, who were discharged from Shenzhen Third People's Hospital from February 2020 to April 2020, were enrolled and followed up until March 4, 2022. COVID-19 survivors received questionnaires of long COVID symptoms and psychological symptoms, pulmonary function tests, chest computed tomography (CT) scans and routine laboratory tests. Two years after infection, 36.6% of patients had at least one symptom of long COVID. Vision impairment and fatigue were the most common symptom. 35.0% of participants still had at least one psychological symptom of anxiety, depression, post-traumatic stress symptoms, and sleep difficulties. Radiographic abnormalities were presented in 50.7% of patients, with the most common features of fibrosis-like lesions and residual ground-glass opacity. Diffuse dysfunction (24.0%) was the main abnormalities of pulmonary function tests. Most laboratory parameters returned to normal range, while persistent abnormalities in kidney and liver function test were observed in a subset of participants after discharge. Two years after COVID-19 infection, persistent symptoms of long COVID and psychological symptoms, as well as abnormalities in pulmonary function tests and CT, were still common in a subset of recovering individuals. These findings were limited by the lack of a healthy control group and pre-COVID assessments, which should be confirmed by further large-scale studies.

show abstract

Section: Discussionmentioning

confidence: 99%

Healthy outcomes of patients with COVID-19 two years after the infection: a prospective cohort study

Liao

et al. 2022

Emerging Microbes & Infections

View full text Add to dashboard Cite

show abstract

“…A significant number of convalescent COVID-19 individuals, with the vast majority of them having a history of mild acute disease, do not make a full recovery and suffer from “Long” COVID for months to years. This post-acute infection clinical syndrome includes non-specific symptoms, such as fatigue, breathlessness, headache, chest pain, abdominal symptoms, myalgias and cognitive impairment [ 2 ]. The prevalence of Long COVID varies greatly between reports; the median proportion of patients with self-reported psychosomatic symptoms post-acute COVID-19 accounted for 72.5% in a systematic review of uncontrolled studies [ 3 ].…”

Section: Long-covid: a Frequent Syndrome With Unclear Pathogenesismentioning

confidence: 99%

Protracted stress-induced hypocortisolemia may account for the clinical and immune manifestations of Long COVID

Yavropoulou¹,

Tsokos²,

Chrousos³

et al. 2022

Clinical Immunology

View full text Add to dashboard Cite

“…It is becoming increasingly clear that COVID-19 is a multisystem disease and can also lead to heart failure, acute kidney failure and neurovascular injuries [5,9,10]. In addition, growing patient testimony and scientific evidence demonstrate that a large number of patients (approximately 2% of the UK population alone) also suffer from post-Viruses 2022, 14, 2728 2 of 15 COVID syndrome (long COVID or post-acute sequelae of COVID-19 (PASC)), which causes debilitating physical or mental symptoms for long periods after infection [5,[11][12][13][14].…”

Section: Emergence Of Covid-19 and Variants Of Concernmentioning

confidence: 99%

Use of Antiandrogens as Therapeutic Agents in COVID-19 Patients

Giotis

Cil

Brooke

2022

Viruses

View full text Add to dashboard Cite

COVID-19, caused by the severe acute respiratory syndrome coronavirus 2 (SARS CoV-2), is estimated to have caused over 6.5 million deaths worldwide. The emergence of fast-evolving SARS-CoV-2 variants of concern alongside increased transmissibility and/or virulence, as well as immune and vaccine escape capabilities, highlight the urgent need for more effective antivirals to combat the disease in the long run along with regularly updated vaccine boosters. One of the early risk factors identified during the COVID-19 pandemic was that men are more likely to become infected by the virus, more likely to develop severe disease and exhibit a higher likelihood of hospitalisation and mortality rates compared to women. An association exists between SARS-CoV-2 infectiveness and disease severity with sex steroid hormones and, in particular, androgens. Several studies underlined the importance of the androgen-mediated regulation of the host protease TMPRSS2 and the cell entry protein ACE2, as well as the key role of these factors in the entry of the virus into target cells. In this context, modulating androgen signalling is a promising strategy to block viral infection, and antiandrogens could be used as a preventative measure at the pre- or early hospitalisation stage of COVID-19 disease. Different antiandrogens, including commercial drugs used to treat metastatic castration-sensitive prostate cancer and other conditions, have been tested as antivirals with varying success. In this review, we summarise the most recent updates concerning the use of antiandrogens as prophylactic and therapeutic options for COVID-19.

show abstract

Long COVID: which symptoms can be attributed to SARS-CoV-2 infection?

Cited by 30 publications

References 11 publications

Healthy outcomes of patients with COVID-19 two years after the infection: a prospective cohort study

Healthy outcomes of patients with COVID-19 two years after the infection: a prospective cohort study

Protracted stress-induced hypocortisolemia may account for the clinical and immune manifestations of Long COVID

Use of Antiandrogens as Therapeutic Agents in COVID-19 Patients

Contact Info

Product

Resources

About